Mirvetuximab soravtansine-gynx


Mirvetuximab soravtansine-gynx

Drug updated on 11/29/2023

Dosage FormInjection (intravenous; 5 mg/mL)
Drug Classreceptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate
Ongoing and
Completed Studies


  • Indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.